JPRN-UMIN000042840Completed未知
Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use) - Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use)
Shionogi & Co., Ltd.0 sites545 target enrollmentStarted: December 24, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 545
Study Overview
Brief Summary
Of 538 patients in the safety analysis set, 156 patients (29.00%) experienced an ADR. Of 383 patients in the effectiveness analysis set, rhinitis severity score change from baseline [mean(SD)] was -1.1(0.8) points at 6 months (n=258) and -2.1(1.0) points at 4 years (n=104). In addition, ratings on the PGI-I scale of >=80% of the patients increased.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
Completed
Unknown
Metreleptin for Subcutaneous Injection Post-Marketing SurveillanceipodystrophyJPRN-UMIN000051667Pharmacovigilance Department Shionogi & Co., Ltd.48
Completed
Not Applicable
Actemra, Long-Term Special Drug Use Surveillance in Takayasu arteritis and Giant cell arteritis patientsTakayasu arteritis, Giant cell arteritisJPRN-UMIN000029056Chugai Pharmaceutical Co. Ltd.132
Completed
Unknown
Adverse Drug Reaction Frequency Investigation of TJ-43JPRN-jRCT1080223212Tsumura & Co.3,300
Completed
Not Applicable
PERJETA® IV Infusion Drug use surveillanceBreast CancerJPRN-UMIN000017699Chugai Pharmaceutical Co., Ltd.261